Serum Biochemical and Hematological Parameters in Dogs with Benign Prostatic Hyperplasia (BPH)
Authors
Abstract:
BACKGROUND: Clinical prostatic diseases occur in 80% of dogs over 5 and 95% over 9 years of age. . It seems that benign prostatic hyperplasia) BPH) affect Scottish terriers more severely than the other breeds. OBJECTIVES: This study aimed to evaluate the changes of biochemical and hematological parameters in BPH dogs. METHODS: Blood samples were collected from 10 male dogs older than five years suffering from BPH which referred to Small Animal Hospital of the Veterinary Faculty of Tehran University. The diagnosis of BPH was based on clinical, laboratory surveys and ultrasonography. 10 normal male dogs with same age, breed and weight were selected as control group. Then serum acid phosphatase (TAP and PAP), CRP, urea, creatinine, total protein, albumin, globulins and hematological parameters were assayed and the results were analyzed by Independent student T-test. Also Pearson’s linear correlation test was used to determine the correlation between TAP, PAP, CRP and ESR with length and width of prostate. RESULTS: The length(p=0.008 (, width (p= 0.01)of prostates were significantly higher in dogs suffering from BPH compared to the healthy dogs .TAP and PAP levels significantly elevated in all dogs in BPH group (approximately 6 times) compared to the controls (P=0.001). Moreover, serumic CRP concentration was elevated in some of BPH dogs (approximately 6 times) (p=0.001). While there were significant ESR elevation in some of dogs in disease group compared to the normal dogs, no significant difference was observed in other biochemical and hematological parameters between two groups (p>0.05). There were a highly significant correlation btween serum TAP and PAP (p≤ 0.01) with prostate’s length and width which was more than CRP. CONCLUSIONS: The serum acid phosphatase, CRP and ESR were elevated in BPH dogs but the increase in serum acid phosphatase was more important than the others. It is recommended that each laboratory should use its own values of acid phosphatase in dogs.
similar resources
Benign Prostatic Hyperplasia (bph)
Comprehensive studies show that the holmium laser is ideal for treating BPH. Holmium laser treatments have been the most rigorously investigated BPH techniques. Over 90 articles have been published from 8 randomized clinical trials and over 30 case studies and comparative series. The American, European, British and Australasian urology associations recommend holmium laser for BPH treatment. Hol...
full textSurgical Options for Benign Prostatic Hyperplasia (BPH)
In 1788 John Hunter first described the pathology of prostatic hyperplasia and its effects on the upper urinary tract. It took a century for the first suprapubic prostatectomy to be carried out in 1887 by AF McGill in Leeds (though Americans tend to claim credit to Fuller in New York in 1894.) The procedure was subsequently p o p u l a r i s e d b y S i r Pe t e r F r e ye r . R e t r o p u b i...
full textPossibilities and Limitations of Phytotherapy for Benign Prostatic Hyperplasia (BPH)
Surgical treatment (transurethral resection or open surgical enucleation of the adenoma) of benign prostatic hyperplasia (BPH) is still the only curative therapy and therefore the "gold standard" for the treatment of BPH. Other treatment modalities have to be judged according to this standard. Despite all improvements in surgical technique and modern anesthesiology, a perioperative mortality ra...
full textBenign prostatic hyperplasia (BPH) management in the primary care setting.
Benign prostate hyperplasia (BPH) occurs in up to 50% of men by age 50, and the incidence increases with age. This common clinical problem is diagnosed by history, including the International Prostate Symptom Score (IPSS) questionnaire, and physical examination by digital rectal examination (DRE). Initial management for BPH includes lifestyle modification, and smooth muscle relaxant alpha blo...
full textTherapeutic Class Overview Benign Prostatic Hyperplasia (BPH) Treatments
Therapeutic Class Overview/Summary: The agents approved for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH) will be the focus of this review. The α-adrenergic blockers including, alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin, reduce smooth-muscle tone in the prostate and bladder neck decreasing lower urinary tract symptoms (LUTS) secondary to BPH. Alfuzo...
full textIs staging of benign prostatic hyperplasia (BPH) feasible?
With better understanding of the natural history of benign prostatic hyperplasia (BPH), the treatment can be tailored to the severity of the disease. The aims of this study were to determine the feasibility of staging BPH according to its severity and choose the optimal therapeutic tool for each category, and for comparing results of various modalities of treatment. Two hundred and twenty-five ...
full textMy Resources
Journal title
volume 11 issue 1
pages 55- 62
publication date 2017-01-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023